Investigational PFO Closure DeviceStandard of Care PFO Closure Device
Investigational PFO Closure Device: Occlutech Flex II PFO Closure Device
Standard of Care PFO Closure Device: Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
Study summary
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Subjects with a PFO and cryptogenic stroke:
* PFO defined as visualization of microbubbles (during Trans Esophageal Echo (TEE)) in the left atrium within three cardiac cycles of right atrial opacification at rest and/or with Valsalva.
* Cryptogenic stroke defined as a stroke of unknown cause.
* Stroke defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:
* Symptoms persisting ≥24 hours OR
* Symptoms persisting \<24 hours with Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) findings of a new, neuroanatomically relevant, cerebral infarct.
Exclusion Criteria:
* Age \< 18 years
* Myocardial Infarction (MI) or unstable angina within 6 months.
* Severe mitral valve stenosis, severe aortic valve stenosis, or severe regurgitation.
* Left Ventricle Ejection Fraction (LVEF) \<35%.
* Uncontrolled hypertension or diabetes mellitus despite medications.
* Subjects contraindicated for aspirin or clopidogrel.
* Presence of other comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results.
* Qualifying stroke with Modified Rankin score \>3.
* Anatomy in which the device would interfere with intracardiac or vascular structures.
* Life expectancy \< 2 years.
* Participation in another clinical study that can interfere with the results of this study
* Exclusion for patients with known causes of ischemic stroke:
* Atrial fibrillation/atrial flutter (chronic or intermittent).
* Left Ventricle (LV) aneurysm, intracardiac thrombus, or tumor.
* Mitral or aortic valve vegetation or prosthesis.
* Aortic arch plaques protruding \>4 mm into the lumen.
* Atherosclerosis or arteriopathy of intra- or extracranial vessels with \>50% diameter stenosis in the artery supplying the infarcted territory.
* Another cause of right-to-left shunting (e.g., an Atrial Septal Defect (ASD) or a fenestrated atrial septum).
* Presence of an arterial hypercoagulable state.
* Lacunar infarct probably due to intrinsic small vessel as the qualifying event, defined as an ischemic stroke in the distribution of a single, small deep penetrating vessel in a patient with any of the following:
* A history of hypertension (except in the first week post stroke).
* A history of diabetes mellitus.
* Age ≥50 years.
* MRI or CT with leukoaraiosis greater than symmetric, well-defined periventricular caps, or bands (European Task Force on Age-Related White Matter Changes rating scale score \>0).
* Arterial dissection as the qualifying event.
Primary outcome measure(s)
Effective Closure Rate of PFO — Twelve Months
Trial sites (48)
Facility
City
Region
Status
Arizona Cardiovascular Research Center
Phoenix
Arizona
Stanford University Medical Center
Stanford
California
Los Robles Medical Center
Thousand Oaks
California
Colorado Heart and Vascular PC / St. Anthony Hospital
Lakewood
Colorado
South Denver Cardiology Associates
Littleton
Colorado
Medstar Washington Hospital Center
Washington D.C.
District of Columbia
Rush University Medical Center
Chicago
Illinois
OSF Saint Francis Medical Center
Peoria
Illinois
University of Louisville
Louisville
Kentucky
MaineHealth
Portland
Maine
Tufts New England Medical Center
Boston
Massachusetts
Massachusetts General Hospital
Boston
Massachusetts
Beth Israel Deaconess Medical Center
Boston
Massachusetts
Baystate Medical Center
Springfield
Massachusetts
University of Michigan
Ann Arbor
Michigan
Essentia Health
Duluth
Minnesota
University of Nebraska Medical Center
Omaha
Nebraska
The Valley Hospital
Paramus
New Jersey
University Hospitals Cleveland Medical Center
Cleveland
Ohio
The Ohio State University
Columbus
Ohio
Ohio Health Research Institute
Columbus
Ohio
Oklahoma Heart Hospital
Oklahoma City
Oklahoma
Oregon Health & Science University
Portland
Oregon
UPMC Presbyterian
Pittsburgh
Pennsylvania
Vanderbilt Medical Center
Nashville
Tennessee
HCA Houston Healthcare Medical Center
Houston
Texas
University of Texas Health Science Center at Houston
Houston
Texas
University of Alberta Mazankowski Heart Institute
Edmonton
Alberta
Vancouver General Hospital
Vancouver
British Columbia
Ottawa Heart Institute
Ottawa
Ontario
Toronto General Hospital
Toronto
Ontario
Centre Hospitalier de l'Université de Montreal (CHUM)
Montreal
Quebec
Institut de Cardiologie de Montréal
Montreal
Quebec
Aarhus University Hospital
Aarhus
Denmark
Rigshospitalet Copenhagen
Copenhagen
Denmark
Heart and Lung Center, Helsinki University Hospital
Helsinki
Finland
CHU Grenoble Alpes
La Tronche
France
Hôpital Privé Jacques Cartier
Massy
France
CHU Toulouse Rangueil
Toulouse
France
Universitaetsklinikum Hamburg-Eppendorf
Hamburg
Free and Hanseatic City of Hamburg
+ 8 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.